Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Novartis’ ofatumumab meets primary endpoints in two phase 3 RMS trials
The late-stage trials – ASCLEPIOS I and II probed the efficacy and safety of ofatumumab 20mg given as a once-monthly subcutaneous injection, in comparison to daily once oral
The late-stage trials – ASCLEPIOS I and II probed the efficacy and safety of ofatumumab 20mg given as a once-monthly subcutaneous injection, in comparison to daily once oral
VNRX-5133 is an injectable beta-lactamase inhibitor (BLI) that features selective and potent in vitro activity against both serine- and metallo-beta-lactamases (MBLs), including ESBL, OXA, KPC, NDM, and VIM
The funding was led by new investor IDG Capital. The existing shareholders Sequoia Capital China, VI Ventures, Legend Star Capital, and LYFE Capital continued to invest. New investors
Fast Track designation is received when a potential new therapy is intended to treat a serious condition and data demonstrate the potential to address an unmet medical need.
Based in Germany, Immatics is a clinical-stage biopharma company engaged in the discovery and development of T-cell redirecting cancer immunotherapies. The German firm is expected to develop T-Cell
Fasenra, which was developed by AstraZeneca’s MedImmune, was in-licensed from BioWa, a subsidiary of Japan-based Kyowa Hakko Kirin. Prior to receiving the orphan drug designation for eosinophilic oesophagitis,
In ONM-500, OncoNano leverages its proprietary pH-sensitive micelle technology to deliver antigens while activating innate immunity for the treatment of cancers caused by the human papilloma virus (HPV).
An “off” episode is a time when a patient’s medications are not working well, causing an increase in PD symptoms, such as tremor and difficulty walking. “Parkinson’s disease
The lead product candidate of Modis Therapeutics is MT1621, an investigational deoxynucleoside substrate enhancement therapy. Currently, MT1621 is in late-stage development for the treatment of Thymidine Kinase 2
The Company is confident it has strong grounds to appeal this decision. The judgment disregards the Company’s compliance with federal and state laws, the unique role its medicines